Pharmacoeconomic evaluation of alprostadil in the pharmacotherapeutic scheme for cerebral infarction / 医学研究生学报

ABSTRACT

Objective:To investigate the clinical efficacy and economic effect of Alprostadil in the pharmacotherapeutic scheme for cerebral infarction.Methods:A total of 156 successfully treated cases of cerebral infarction were selected from those admitted from March 2003 to March 2004 and divided into two pharmacotherapeutic groups,with Alprostadil given to Group Ⅰ.The data were evaluated and compared by pharmacoeconomic cost-effect analysis.Results:The costs were $11 271.47 and $8 147.06,and the effectiveness rates were 84.21% and 70.00% respectively in the two groups,with the cost-effect ratios of 133.86 and $114.34 / unit effectiveness.It cost $219.87 for Group Ⅰ to increase a unit of effectiveness over Group Ⅱ.Conclusion:Group Ⅰ had a higher effectiveness rate,while Group Ⅱ a lower cost-effect ratio.